Zobrazeno 1 - 4
of 4
pro vyhledávání: '"August F Zabernigg"'
Autor:
Gabriel Rinnerthaler, Simon P. Gampenrieder, Christoph Tinchon, Andreas Petzer, Marija Balic, Sonja Heibl, Margit Sandholzer, August F. Zabernigg, Daniel Egle, Christopher Hager, Petra Pichler, Florian Roitner, Johannes Andel, Kathrin Strasser-Weippl, Michael Knauer, Michael Hubalek, Christian F. Singer, Richard Greil
Publikováno v:
Cancer Research. 83:P3-05
Background: Hormone-receptor (HR) status, HER2 Status, de novo metastatic disease, distant recurrence-free interval (DRFI), and visceral disease are known prognostic factors in metastatic breast cancer (MBC). Therefore, in the majority of clinical tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b0e32f9a0b2d18076dbbc62f6d3aed29
https://doi.org/10.1158/1538-7445.sabcs22-p3-05-49
https://doi.org/10.1158/1538-7445.sabcs22-p3-05-49
Autor:
Simon Peter Gampenrieder, Gabriel Rinnerthaler, Christoph Tinchon, Andreas Petzer, Marij Balic, Sonja Heibl, August F Zabernigg, Daniel Egle, Margit Sandholzer, Florian Roitner, Johannes Andel, Petra Pichler, Christopher Hager, Michael Knauer, Michael Hubalek, Christian F Singer, Richard Greil
Publikováno v:
Cancer Research. 82:P1-21
Background: BM are generally associated with poor prognosis and with neurological impairments making BM a major limitation of life expectancy and quality of life in MBC. Real-world data are needed in order to quantify and better characterize this spe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::14f8681a4166c26a9774b3cbe1cec808
https://doi.org/10.1158/1538-7445.sabcs21-p1-21-08
https://doi.org/10.1158/1538-7445.sabcs21-p1-21-08
Autor:
Gabriel Rinnerthaler, Simon P Gampenrieder, Christoph Tinchon, Andreas Petzer Petzer, Marija Balic, Heibl Sonja, August F Zabernigg, Daniel Egle, Margit Sandholzer, Florian Roitner, Johannes Andel, Petra Pichler, Christophe Hager, Michael Hubalek, Michael Knauer, Christian F Singer, Richard Greil
Publikováno v:
Cancer Research. 82:P1-16
Background: Despite the advances by targeted therapies, particularly in HER2-positive and hormone receptor (HR)-positive metastatic breast cancer (MBC), chemotherapy remains a mainstay of the treatment in all breast cancer subtypes. Response probabil
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4aa41106f53bd0c171b3d45688056552
https://doi.org/10.1158/1538-7445.sabcs21-p1-16-03
https://doi.org/10.1158/1538-7445.sabcs21-p1-16-03
Autor:
Simon P. Gampenrieder, Gabriel Rinnerthaler, Christoph Tinchon, Andreas Petzer, Marija Balic, Sonja Heibl, Margit Sandholzer, August F. Zabernigg, Daniel Egle, Christopher Hager, Petra Pichler, Florian Roitner, Johannes Andel, Kathrin Strasser-Weippl, Michael Knauer, Michael Hubalek, Christian F. Singer, Richard Greil
Publikováno v:
Cancer Research. 83:P4-01
Background: New anti-HER2 drugs such as tucatinib and trastuzumab deruxtecan (T-DXd) have shown to improve survival of HER2+ MBC in clinical phase III trials. To allow a future confirmation of this survival advantage in real world, we evaluated the p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::70a4b8526bec048e7dcf2bc9c4a9d0b4
https://doi.org/10.1158/1538-7445.sabcs22-p4-01-27
https://doi.org/10.1158/1538-7445.sabcs22-p4-01-27